IP Library Patent Application 12340219
Patent Application
App. No. 12/340,219

Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/340,219
Abstract

Lyophilized pharmaceutical compositions comprise a natriuretic peptide, a buffer and a bulking agent that are stable at room temperature. Preferably, for a fill volume of 1 mL (pre-lyophilization), the total cake mass, post-lyophilization, is 30-175 mg. Preferably, the natriuretic peptide is ularitide or a pharmaceutically acceptable salt thereof. Various embodiments of the compositions may further comprise at least one of an acid and a base. In some embodiments, the pH of the compositions is between 4.0 and 6.0. In addition, various embodiments of the compositions may further comprise a stabilizing agent. In some embodiments, the compositions are isotonic. Preferably, the compositions are used for the treatment of cardiac conditions. The invention also relates to methods for preparing such compositions.

Claims (83)

1 . A lyophilized pharmaceutical composition comprising:

(a) a natriuretic peptide;

(b) a bulking agent; and

(c) a buffer.

2 . The composition of claim 1 wherein the natriuretic peptide is selected from the group consisting of atrial natriuretic peptide, brain natriuretic peptide, C-type natriuretic peptide, dendroaspis natriuretic peptide and ularitide.

3 . The composition of claim 2 wherein the natriuretic peptide is ularitide.

4 . The composition of claim 1 wherein the bulking agent is selected from the group consisting of mannitol and glycine.

5 . The composition of claim 1 wherein the buffer is histidine.

6 . The composition of claim 1 wherein the composition further comprises a stabilizing agent.

7 . The composition of claim 6 wherein the stabilizing agent is selected from the group consisting of sucrose and trehalose.

8 . The composition of claim 1 wherein the composition further comprises at least one of an acid and a base.

9 . The composition of claim 8 wherein the acid is hydrochloric acid.

10 . The composition of claim 8 wherein the base is sodium hydroxide.

11 . The composition of claim 1 wherein the pH of the composition is 4.0-6.0.

12 . The composition of claim 1 wherein the lyophilized composition has a post-lyophilization total cake mass of 30-175 mg for a fill volume of 1 mL (pre-lyophilization).

13 . The composition of claim 1 comprising:

(a) 0.1-10 mg/mL natriuretic peptide;

(b) 1-10% bulking agent; and

(c) 1-25 mM buffer.

14 . The composition of claim 1 comprising:

(a) 0.1-10 mg/mL ularitide;

(b) 1-10% bulking agent; and

(c) 1-25mM buffer.

15 . The composition of claim 1 comprising:

(a) 0.1-10 mg/mL ularitide;

(b) 1-10% bulking agent; and

(c) 1-25 mM buffer;

wherein the pH of the composition is 4.0-6.0.

16 . The composition of claim 1 comprising:

(a) 0.1-10 mg/mL ularitide;

(b) 1-10% bulking agent;

(c) 1-25 mM buffer; and

(d) 1-10% stabilizing agent.

17 . The composition of claim 1 comprising:

(a) 0.1-10 mg/mL ularitide;

(b) 1-10% bulking agent;

(c) 1-25 mM buffer; and

(d) 1-10% stabilizing agent;

wherein the pH of the composition is 4.0-6.0.

18 . The composition of claim 15 comprising:

(a) 2 mg/mL ularitide;

(b) 5% mannitol; and

(c) 10 mM histidine;

wherein the pH of the composition is 5.5.

19 . The composition of claim 17 comprising:

(a) 2 mg/mL ularitide;

(b) 5% mannitol;

(c) 10 mM histidine; and

(d) 1% sucrose;

wherein the pH of the composition is 5.5.

20 . The composition of claim 15 comprising:

(a) 2 mg/mL ularitide;

(b) 6% glycine; and

(c) 10 mM histidine;

wherein the pH of the composition is 5.5.

21 . The composition of claim 17 comprising:

(a) 2 mg/mL ularitide;

(b) 6% glycine;

(c) 10 mM histidine; and

(d) 1% sucrose,

wherein the pH of the composition is 5.5.

22 . The composition of claim 15 comprising:

(a) 1-3 mg/mL ularitide;

(b) 3-7% mannitol; and

(c) 8-12 mM histidine;

wherein the pH of the composition is 5.0-6.0.

23 . The composition of claim 17 comprising:

(a) 1-3 mg/mL ularitide;

(b) 3-7% mannitol;

(c) 8-12 mM histidine; and

(d) 0.25-2% sucrose;

wherein the pH of the composition is 5.0-6.0.

24 . The composition of claim 15 comprising:

(a) 1-3 mg/mL ularitide;

(b) 4-8% glycine; and

(c) 8-12 mM histidine;

wherein the pH of the composition is 5.0-6.0.

25 . The composition of claim 17 comprising:

(a) 1-3 mg/mL ularitide;

(b) 4-6% glycine;

(c) 8-12 mM histidine; and

(d) 0.25-2% sucrose,

wherein the pH of the composition is 5.0-6.0.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2011
From: EKR THERAPEUTICS, INC.
To: CARDIOPEP PHARMA GMBH
Reel/Frame 026036/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2009
From: GUPTA, SUPRIYA; MI, YANLI
To: EKR THERAPEUTICS, INC.
Reel/Frame 022261/0189 →